US orphan drug status for Bayer's regorafenib
This article was originally published in Scrip
The US FDA has granted orphan drug status to Bayer's investigational targeted anticancer regorafenib (BAY 73-4506) for the treatment of gastrointestinal stromal tumours (GIST).
You may also be interested in...
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.
Executives On The Move: TG Therapeutics Brings Aboard Pioneering Academic Scientist for Its C-Suite, Roche Decides On A Research Exec And Ascendis Announces A New Global Officer
TG Therapeutics, developing treatments for B-cell malignancies, adds an authority in lymphoma as CSO, and Roche hires a Broad Institute exec to head up Genentech’s research and early development. Plus, Ascendis Pharma, with programs in endocrinology/oncology, picks a global chief commercial officer.